China Gender-affirming Hormone Therapy Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-40
SponsorPeking University Third Hospital
About this trial
Data about transgender medical care, especially the gender-affirming hormone therapy (GAHT) is extremely insufficient in China. Few evidence exists in the physical and psychological effects of the hormonal treatment in Chinese transgender population. CGAHT is designed to describe the social and mental condition of transgender people who are seeking for formal GAHT, and to investigate the physical and psychological effects of GAHT on this population in China.
Eligibility criteria
Qualifiers
Transgender men and women
Meet criteria of Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) for gender dysphoria
Aged between 18 to 40 years
People desire to start the GAHT
Disqualifiers
Disorders of sex development
Who has fertility demand but have not made fertility preservation
With contradictions of GAHT
Comorbid diseases are not under control
Trial design
Treatments tested in this trial
- GAHT for transgender men
- GAHT for transgender women
Treatment groups
240 Participants
are divided into 3 treatment groupsSponsors and collaborators
Peking University Third Hospital
Lead sponsor
Tsinghua University
Collaborator
Source ClinicalTrials.gov